1 / 1

Identification of Potent Compounds in Pathway X: EC50 Bioactivity Assessment

This study focuses on compounds that act as agonists in pathway X, specifically those tested in functional assays with potency less than 1 µM. We filter the data for EC50 bioactivity entries, ensuring the relation is not equal to greater than. Additionally, we convert activity units from nM to µM using the -LogEC50 methodology. The analysis is conducted by Chris Chau at GSK, emphasizing the significance of identifying potent compounds in therapeutic development.

meryl
Télécharger la présentation

Identification of Potent Compounds in Pathway X: EC50 Bioactivity Assessment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Question 14 : Compounds that agonizes targets in pathway X assayed in only functional assays with a potency <1 uM Filter for this specific question: Select EC50 bioactivity data entry Relation not equal to > Convert activity unit from nM/-LogEC50 to uM Assay with potency <1uM Chris Chau(GSK) Chris Chau (GSK)

More Related